THE WOODLANDS, TX, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced the next CEO Corner segment has been published on the Company’s website. For the segment, Brad Hauser, President and CEO of Autonomix, discussed two key areas that are shaping the Company’s path forward: protecting the strength of its platform through intellectual property, and explorin ...

EORTC QLQ-C30 subgroup results confirm broad and durable quality-of-life improvements across disease stages and metastasis status, complementing previously reported pain reduction and opioid-free outcomes Late-stage patients showed substantial improvements, suggesting ablation provided clinically meaningful changes even in advanced severe disease THE WOODLANDS, TX, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to ...

Core Insights - Autonomix Medical, Inc. will present at the TCT 2025 Annual Scientific Conference, showcasing its innovative nerve-targeted treatment technology [1][2] - The presentations will focus on the initial phase results of a clinical study aimed at alleviating pain in pancreatic cancer patients through transvascular energy delivery [2] Company Overview - Autonomix is a medical device company dedicated to advancing technologies for diagnosing and treating diseases related to the nervous system [4] - The company's platform technology includes a catheter-based microchip sensing array designed to detect and differentiate neural signals with high sensitivity [4][5] - Initial development efforts are concentrated on pain management, particularly for pancreatic cancer, which currently lacks effective treatment options [5] Conference Details - TCT 2025 is a four-day educational conference focused on interventional cardiovascular medicine, taking place from October 25-28, 2025, in San Francisco [3] - The conference is organized by the Cardiovascular Research Foundation and has grown significantly since its inception in 1988, now attracting thousands of attendees [3]

Core Insights - Autonomix Medical, Inc. will participate in the 2025 Maxim Growth Summit on October 22-23, 2025, in New York, showcasing its commitment to advancing precision nerve-targeted treatments [1][2] Company Overview - Autonomix is a medical device company focused on innovative technologies for diagnosing and treating diseases of the nervous system [4] - The company's first-in-class platform includes a catheter-based microchip sensing array designed to detect and differentiate neural signals with greater sensitivity than existing technologies [4] - The technology aims to enable transvascular diagnosis and treatment of peripheral nervous system diseases throughout the body [4] Technology Development - Initial development of the technology targets pain management, specifically for pancreatic cancer, which is known for causing severe pain and lacks reliable treatment options [5] - The technology serves as a platform for addressing various indications, including cardiology, hypertension, and chronic pain management [5] - The technology is currently investigational and has not yet received marketing clearance in the United States [5]

Core Insights - Autonomix Medical, Inc. has received a new patent that enhances its position in a multi-billion-dollar market for nerve-targeted treatments, particularly in cardiology and related fields [1][2][3] Intellectual Property Development - The company has over 120 issued and pending patent applications, indicating a strong commitment to building a comprehensive global intellectual property portfolio in nerve-sensing and modulation [1] - The newly issued U.S. Patent No. 12,369,852 covers systems and methods for sensing autonomic signals and delivering precise cardiac therapies [1][3] Market Opportunity - The patent positions Autonomix to capitalize on high-growth areas in cardiology, including renal denervation for hypertension, arrhythmia management, heart failure, and refractory angina [2][3] - The technology aims to provide precision therapies that could reduce the reliance on systemic beta-blockers, which often have undesirable side effects [2][3] Technological Advancements - Autonomix's technology includes a catheter-based microchip sensing array designed to detect and differentiate neural signals with greater sensitivity than existing technologies [5] - The platform has the potential to address various indications across multiple therapeutic areas, including cardiology, hypertension, and chronic pain management [4][6] Initial Focus and Future Potential - The company is initially developing its technology for pain management, specifically targeting pancreatic cancer, which is known for causing severe pain [6] - The investigational nature of the technology indicates that it has not yet received marketing clearance in the United States, suggesting ongoing development and potential future applications [6]

Core Insights - Autonomix Medical, Inc. has initiated a Good Laboratory Practice (GLP) preclinical study for its Sensing and RF Ablation System aimed at treating pancreatic cancer pain, marking a significant step towards regulatory approval [1][2][3] - The company is on track to submit an Investigational Device Exemption (IDE) to the FDA, with plans to commence U.S. clinical trials in 2026 if approved [1][3] - Autonomix's technology platform has the potential to address multiple high-need therapeutic areas, including cardiology, resistant hypertension, interventional pain management, and gastrointestinal disorders [4][7] Company Overview - Autonomix is focused on advancing innovative technologies for diagnosing and treating diseases related to the nervous system, utilizing a catheter-based microchip sensing array for enhanced neural signal detection [6][7] - The company's initial development efforts are concentrated on pain management, specifically targeting pancreatic cancer, which currently lacks effective treatment options [7] Research Institute Collaboration - The GLP study is being conducted at CBSET, a leading translational research institute in Massachusetts, known for its high-quality biomedical research services [5]

Core Viewpoint - Autonomix Medical, Inc. has initiated a Good Laboratory Practice (GLP) preclinical study for its Sensing and RF Ablation System aimed at treating pancreatic cancer pain, marking a significant step towards regulatory approval and potential clinical trials in the U.S. by 2026 [1][2][3] Company Overview - Autonomix is focused on advancing innovative medical technologies for diagnosing and treating diseases related to the nervous system, utilizing a first-in-class platform technology that includes a catheter-based microchip sensing array [6][7] - The company's technology aims to provide transvascular diagnosis and treatment of peripheral nervous system diseases, with initial development targeting pain management in pancreatic cancer [7] Regulatory Pathway - The GLP study is essential for ensuring the reliability and integrity of Autonomix's devices, which is a prerequisite for submitting data to the FDA for Investigational Device Exemption (IDE) clinical trials [2] - The company is on track to file its IDE application, with plans to commence clinical studies in the following year if approved [3] Technological Potential - Autonomix's technology has the potential to address multiple high-need therapeutic areas, including cardiology, resistant hypertension, interventional pain management, and gastrointestinal disorders [4][6] - The platform is designed to tackle a wide spectrum of diseases, indicating a broad market opportunity for the company [7]

Core Insights - Autonomix Medical, Inc. is presenting findings from its first-in-human proof-of-concept clinical trial at the 2025 CIRSE Annual Congress in Barcelona, Spain, from September 13-17, 2025 [1] - The presentation will focus on the application of artificial intelligence in interventional radiology, specifically addressing pain mitigation in pancreatic adenocarcinoma through neurolysis via transvascular radiofrequency ablation [2] Company Overview - Autonomix is a medical device company dedicated to advancing technologies for diagnosing and treating diseases of the nervous system, utilizing a catheter-based microchip sensing array for enhanced neural signal detection [4] - The company's initial focus is on treating pain associated with pancreatic cancer, a condition currently lacking reliable treatment options, with potential applications across various medical fields including cardiology and chronic pain management [5] Event Details - The presentation will be led by Marco Bedoya, VP of Research and Development, during the session titled "AI in IR: Machine Learning, SOP and Collaborative Development" on September 15, 2025, from 4:15 PM to 5:15 PM CEST [2]

Core Insights - Autonomix Medical, Inc. has announced positive results from a post hoc analysis of its proof-of-concept human clinical trial ("PoC 1"), highlighting sustained pain reduction, quality of life improvements, and 100% opioid-free outcomes [2][4] Company Overview - Autonomix is a medical device company focused on innovative technologies for diagnosing and treating diseases of the nervous system, utilizing a first-in-class catheter-based microchip sensing array [3] - The technology aims to enable transvascular diagnosis and treatment of peripheral nervous system diseases, potentially applicable across various medical fields [3][4] Technology Development - The initial focus of the technology is on pain management, particularly for pancreatic cancer, which is known for causing severe pain and lacks effective treatment options [4] - The platform technology has the potential to address multiple indications, including cardiology, hypertension, and chronic pain management [4]

Core Insights - Autonomix Medical, Inc. has reported long-term data indicating a nearly 66% reduction in pain for patients with severe pancreatic cancer pain, with a mean reduction of 5.08 on the VAS pain scale [1][7] - 100% of responders were opioid-free at the 3-month follow-up, highlighting the potential of the technology as a non-opioid alternative for pain management [2][7] - The company is expanding its proof-of-concept studies to include additional visceral cancers, indicating a broader market opportunity [3][4] Group 1: Study Results - The PoC 1 study demonstrated statistically significant pain relief as early as 24 hours post-procedure, with sustained relief lasting up to five months [3][9] - Responding patients reported a mean 76.5% improvement in global health and a 51.5% improvement in functional ability at 7 days post-procedure [7][9] - The study enrolled 20 patients, with 19 treated successfully, and showed a strong safety profile with no serious adverse events related to the procedure [11][9] Group 2: Technology and Market Potential - Autonomix's technology is a platform that could address various indications, including cardiology and chronic pain management, beyond just cancer pain [4][12] - The follow-on PoC 2 phase aims to evaluate pain management for additional visceral cancers, expanding the potential addressable market significantly [3][4] - The company's catheter-based microchip sensing array technology is designed to detect and differentiate neural signals, which may enhance treatment efficacy [10][12]